Life Science Real Estate in the COVID-19 Era

December 2020
Investor attention on life science real estate is accelerating, with pandemic-related tailwinds and an undersupply of lab space driving pricing higher in top markets. What are the sector’s largest investors up to, and where might future opportunities be?

About the Author

Daniel Littman is Senior Analyst for Capital Markets Research in Newmark’s Manhattan office.

For More Information

Alexander (Sandy) Paul, Senior Managing Director of National Research, APaul@ngkf.com

We use cookies for analytics (including your interaction with and navigation of and with this site), and to improve our site and services. For more information about our use of cookies, the information we collect, how it is used, and your rights, see our Privacy Statement.